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ABBREVIATIONS  
 
AT - Absorbance Test  
   
AS - Absorbance Sample  
   
ACS - Acute Coronary Syndrome 
   
AMI - Acute Myocardial Infarction 
   
BP - Blood Pressure  
  
BH4 - Tetrahydrobiopterin  
   
C - Centigrade 
  
CAD - Coronary Artery Disease 
   
CK-MB - Creatine Kinase – MB Iso form 
   
CM - Centimetre  
   
CRP - C-reactive Protein 
   
CVS - Cardio Vascular System 
   
df - Degree of freedom  
   
dl - deci liter  
   
ECG - Electro Cardio Gram 
   
FBG - Fasting Blood Glucose  
   
G - Grams  
   
GOD-POD - Glucose Oxidase – Peroxidase  
   
GTP - Guonosine tri phosphate 
   
GTP-CH  - Guonosine tri phosphate – Cyclo hydrolase 
   
HDL - High Density Lipo proteins 
   
HIV - Human Immuno Deficiency Virus.   
   
ICCU - Intensive Coronary Cardiac Unit 
   
IHD - Ischaemic Heart Disease 
  
L - Litre  
   
LDL - Low Density Lipo proteins 
   
LVEF - Left Ventricular Ejection Fraction 
   
MACE - Massive Adverse Cardiac Events 
   
MMOL  - Milli Mol / litre  
   
ML - Milli litre  
   
μL - Micro litre 
   
N - Neopterin 
   
NH2 TP - Dihydro neopterintriphosphate  
   
nm - nano meter  
   
nmOL/l - Nano mole / litre  
   
NQMI - Non Q Wave Myocardial Infarction 
   
mg - Milligram  
   
Min - Minutes  
   
O.D - Optical Density 
   
OP - Out Patient  
   
P - Probability  
   
PH - Previous Hospitalisation  
   
RT - Room Temperature 
   
Sig - Significance  
  
Std - Standard  
   
SR - Serum  
   
T - Temperature  
   
T-Cell  - Thymus derived  
   
TIMI - Thrombolysis in myocardial infarction 
   
VLDL - Very Low Density Lipo proteins 
   
U - Units  
   
US - Unstable Angina  
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INTRODUCTION  
            Acute myocardial infarction (AMI) is one of the most common diseases 
in hospitalised patients in industrialised countries. The early (30-day) mortality 
rate from AMI is ~30%, with more than half of these deaths occurring before 
the stricken individual reaches the hospital. Although the mortality rate after 
admission for AMI declined by ~30% over the past two decades, 
approximately 1 of every 25 patients who survives the initial hospitalisation 
dies in the first year after AMI . Mortality is approximately four fold higher in 
elderly patients (over age 75) compared with younger patients (1). 
 
 AMI is one of the important medical emergencies admitted in the 
hospitals.  It is characterised by the presence of clinical features like sudden 
onset of severe chest pain with dysponea, palpitation  and profuse sweating 
leading to cardiac arrythmias, cardiogenic shock, cardiac failure and death if 
not treated early (2).  
  
 Among the biomarkers for diagnosis and prognosis in AMI, the 
Neopterin, a pteridine derivative is considered to be one of the new novel          
bio-markers which is found to be elevated in patients with AMI. 
 
 Neopterin was first isolated from larvae of bee in 1963 (3).  Eventually   
Neopterin was identified as the fluorescent component that was elevated in 
the urine of mice with Ehrlich ascites tumour (4).    Now it is proved that this is 
the exclusive product of  monocytes / macrophages that have been stimulated 
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by interferon gamma, a  cytokine that is produced by activated T-lymphocytes 
and nature killer cells (5).     
  
 Biochemically Neopterin belongs to pteridines group. It is a catabolic 
product of guonosine-tri-phosphate [GTP]. Its molecular formula is C9H11N5O4. 
Its molecular mass is 253.215.  Neopterin is synthesised from GTP via GTP 
cyclohydrolase(GTP-CH). The activity of GTP-CH can be greatly enhanced by 
interferon gamma (6).  
   
 7,8 dihydroneopterintriphosphate (NH2TP) is on the biosynthetic 
pathway of 5,6,7,8 tetrahydrobiopterin (BH4). BH4 represents the electron 
donor in the amino acid metabolic pathways. Human monocytes / 
macrophages lack the enzyme 6-pyruvoyl-tetra-hydro biopterin synthase 
which converts NH2TP to 6-pyruvoyl-tetra-hydro biopterin.  Thus, in these 
cells NH2TP accumulates and after hydrolysis by phosphatases is excreted as  
dihydroneopterin or Neopterin (7).  
 
 Neopterin reflects the of monocytes / macrophages activity stimulated 
by interferon gamma, a cytokine that is produced by the activated                     
T-lymphocytes the nature killer cells (8).   Estimation of Serum levels of 
Neopterin is a new novel biomarker in AMI and seems to be a prognostic 
marker for MACE in AMI. 
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AIMS & OBJECTIVES  
 
 To    elucidate   the   role    of Neopterin   levels   and its   short   term 
prognostic significance in AMI, the following objectives are formulated. 
 
 
1. Estimation of levels of Serum Neopterin in AMI. 
 
2. Significance of levels of Serum Neopterin during the treatment in the   
ICCU. 
 
3. Correlation of levels of Serum Neopterin with the other cardiac risk   
factors. 
 
4. The role of Neopterin for the prognostic stratification in AMI. 
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REVIEW OF LITERATURE  
 Studies have reported an association between Neopterin and the 
extent of atherosclerosis.  Neopterin is elevated in patients with CAD and 
peripheral vascular disease (9).    
 
 The atheromatous plaque in AMI is characterised by presence of            
T-cells and a large amount of monocytes / macrophages in the shoulder 
region of the plaque.  Activation of monocytes / macrophages produce            
pro-inflammatory cytokines giving rise to a rupture prone plaque.  The 
activation of monocytes / macrophages may be due to the interferon produced 
by activated T-lymphocytes and is reflected by the high levels of             
Neopterin (10). 
 
 A central role in the pathogenesis of AMI is attributed to monocyte / 
macrophage activation.  Neopterin,  a  pteridine  derivative  is  synthesised  by  
monocyte / macrophage  upon  stimulation  with  interferon. Neopterin levels 
are a useful tool to monitor monocyte / macrophage in AMI (11).    
  
 The Serum Neopterin concentration is associated with presence of 
angiographically demonstrated  complex  defects in  patients  with  AMI  and 
may  represents  a  marker  of  coronary  disease  activity (12).  
 
 Neopterin was identified as fluorescent component. It is clear that 
Neopterin can be detected in most body fluids (13). 
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 Inflammation plays a key role in the pathogenesis of atherosclerosis. 
Infiltration of neutrophils and monocytes / macrophages is detected in the 
vessel wall in patients with CAD.  Macrophages activated by interferon 
gamma synthesize metalloproteinases and Neopterin, a pteridine derivative 
that has been used as a immunomarker. Neopterin as a marker of 
macrophage activation is significantly increased in patients with AMI, 
supporting the hypothesis of monocyte / macrophage activation in patients 
with AMI (14).  
 
 Atherosclerosis is a complex disease that involves lipoprotein influx 
and modification increased pro-oxidant stress and inflammatory angiogenic 
and fibro proliferative responses inter mingled with extra cellular matrix and 
smooth muscle cell proliferation resulting in the formation of atherosclerotic 
plaque (15). 
 
 The concept of response to injury, hypothesis considers   
atherosclerosis as a chronic inflammatory response of the arterial wall to the 
injured endothelium (16). 
   
 Inflammation plays important role in the pathogenesis of 
atherosclerosis.  Atherosclerosis remains the major cause of death and pre 
mature disability in the developed countries. 
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 Formation of fatty streak, the earliest phase of atherogenesis involves 
recruitment of leucocytes due to expression of leucocyte adhesion molecule 
on endothelial cells in turn triggered by primary pro–inflammatory cytokines. 
  
 Subsequent migration of inflammatory cells into the sub-endothelial 
space requires chemotaxis controlled by chemokines induced by the primary 
cytokines.  Mononuclear cells within this initial infiltrate as well as intrinsic 
vascular cells subsequently release growth factors that stimulate proliferation 
of smooth muscle cells and hence the progression of plaques (17).  
 
 Inflammation is a major feature of atherothrombosis, and there is   
growing evidence of an association between systemic inflammation and the   
occurrence of stroke, peripheral artery disease, unstable angina, and IHD. 
Such an inflammatory component may be the final common result of a   
variety of infectious and non-infectious inflammatory stimuli and of the   
individual immunologic and inflammatory response (18).   
  
 Triggers of plaque rupture and novel risk factors for ACS are : 
Neopterin, Lselectin, Macrophage inflammatory peptide, Interleukin, Intra 
Cellular Adhesion, Vascular Cell Adhesion, Leucocyte Count, Heat Shock 
Proteins,  Matrix   Metaloprotease 9 (MMMP  9) (19).  
  
 Inflammation plays a role in the pathogenesis IHD.  It is now accepted   
that inflammatory processes takes place within the atheromartous lesions and   
significantly contribute to the progression of stenosis and acute coronary   
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events.  Studies have shown an association between markers of inflammation 
and the presence of coronary atherosclerosis, as well as the exacerbation of 
inflammation during acute myocardial ischemia.  Several inflammatory 
markers have been shown to represent true cardio vascular risk factors. In 
this respect the CRP, the Neopterin and the Leucocyte count are all of 
particular interest.    Studies suggest that high levels of Serum Neopterin may 
be a marker of atheromatous   plaque vulnerability and   identify  patients at  
increased   risk   of   serious   coronary   events.  The   results   of   these   
studies reveal   that   Neopterin   may be a marker of coronary disease activity 
rather than   a   marker of presence of CAD ( 20).  
 
 Inflammation plays a vital role in atherosclerosis and coronary heart 
disease. Inflammatory processes of the coronary arterial wall are involved in 
plaque formation, progression and finally plaque instability leading to clinical 
manifestations of stable coronary artery disease and acute coronary 
syndromes. Biomarkers of inflammation emerged as potentially useful tools 
for risk stratification (21). 
 
 Studies also found an association between Neopterin levels and 
impaired LVEF (22). 
 
 Elevated Serum levels of Neopterin, an immune modulator secreted by 
activated macrophages with patients in ACS. Serum Neopterin is an 
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independent predictor of MACE in patients with ACS. This marker of 
macrophage may be useful for risk stratification in patients with AMI (23). 
 
 Alteration in Serum Neopterin correlate with macrophage activation 
and TIMI risk course.  Serum Neopterin concentrations have a high 
correlation with TIMI risk course and may represent a marker useful in stratify 
patients with ACS (24). 
 
 Clinical studies performed recently proved great role of inflammatory 
processes in development of atherosclerosis. These inflammatory biomarkers 
are used in the diagnosis and identification of patients with unstable angina 
pectoris and myocardial infarct. (25). 
 
 Serum Neopterin concentrations have a high correlation with TIMI risk 
scores and may represent a marker useful in stratifying patients with                
ACS (26). 
 
 Patients  with  AMI  and  UA  have  significantly  have  higher  levels  of 
Neopterin than  patients  with  remote   AMI  or  Control  group  patients (27).    
 
 Neopterin was  significantly  increased  in  patients  with  stable  CAD  
and more  pronounced  in  patients  with  AMI  than  Control  group              
patients (28).   
 
 Neopterin is significantly increased in patients with ACS and elevated    
Neopterin levels predict MACE during follow-up (29).  
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 Rapid CAD progression in patients with stable CAD is associated with 
increased Neopterin levels (30). 
 
 Serum Neopterin levels is an independent predictor of MACE (31).     
 
 Patients who developed MACE during follow-up had significantly higher 
Neopterin  levels  than  control  group  patients (32).     
 
 Patients  with   stable  CAD  and  with  MACE  during  follow-up had 
significantly higher Neopterin  levels   than  those  without  MACE (33).  
 
 High Serum Neopterin levels are associated with the presence of 
demonstrated complex lesions (34). 
 
 Neopterin levels are a useful marker of the severity CAD (35).        
 
 Serum Neopterin levels predict MACE in patients with AMI (36).   
 
 Serum    neopterin levels predict MACE in patients with NQMI (37).   
 
 Neopterin levels are increased after stroke (38).  
 
 Patients with carotid athersclerosis have higher Neopterin levels than 
in patients without (39).  
  
 Neopterin a by-product of guonosine tri-phosphate pathway, is 
produced by activated macrophages and serves as an activation marker for 
monocytes/ macrophages (40). 
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        Long term prognostic value of Neopterin a novel marker of monocyte 
activation in patients with acute coronary sydrome.  Neopterin is a soluble 
marker of monocyte activation and elevated levels are of prognostic               
values (41).   
 
 Inflammation plays a key role in the initiation and progression of 
atherosclerosis but also in the patho-physiology of atheromatous plaque 
disruption and the development of ACS. 
  
 Neopterin is a marker of inflammation and of immune system 
activation, it is synthesised by macrophages that, once activated (42).   
  
 Increased monocyte activation detected by an elevated plasma 
Neopterin level identifies patients at long term risk of death or recurrent acute 
coronary events after ACS.   
 
 Monocyte activation is believed to be playing an important role in the 
pathogenesis of ACS.  Neopterin is a soluble marker of monocyte activation, 
and elevated levels are of prognostic value in patients with ACS (43).           
 
 Neopterin levels predict future major cardiac and vascular adverse 
events.  This  molecule  can  be  considered  as  a  useful  marker  of  
atherosclerotic  plaque  activity,  permitting  the  identification  of  the  subjects  
at  highest  risk  for  Major  Adverse  Cardiovascular   Events.  In  line  with  
above  mentioned  evidences,  patients  with  high  Neopterin  levels  may  
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require  aggressive  risk  factor  modification  and  intensive  medical  
treatment  irrespective  of  the  severity  of  their  CAD.  This  data  suggest  a  
potential  clinical  use  of  Neopterin as  a  marker  for  disease  activity  in  
patients  with   Cardiovascular  Disease (44). 
 
 Recent data indicate that Serum levels of Neopterin are elevated in 
patients with coronary artery disease (CAD) and seem to be a prognostic 
marker for Major Adverse Cardiovascular Events. Based on many recent 
research works all over the world this molecule can be rendered a useful 
inflammatory marker of atherosclerotic plaque activity, permitting the 
identification of subjects at higher risk for Major Adverse Cardiovascular 
Events (45). 
 
 Neopterin levels a marker of macrophage activation predict 
cardiovascular events in ACS (46).   
 
 Neopterin  is  an  independent  predictor  of  all  causes  and  cardio  
vascular  mortality  in  individuals  with  or  without  CAD (47). 
  
 Serum Neopterin levels can be considered as an independent predictor 
of major adverse cardiac events.   This marker of macrophage activation  may  
be    useful  for  risk  stratification  in  cardiac  patients (48). 
 
 Neopterin concentrations usually correlate with the activity of the 
disease.  Elevated Neopterin concentration are among the best predictors of 
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adverse outcome in patients in cardiovascular diseases, HIV infections and 
various types of cancers (49). 
  
 Neopterin is an activation marker for monocytes / macrophages, and 
circulating levels of Neopterin are elevated in patients with coronary complex 
lesions in AMI (50).   
 
 Neopterin is one the markers of inflammation produced by the 
macrophages when stimulated by interferons and released by activated                   
T-cells (51). 
 
 BRAUNWALD had initially proposed risk stratification based on the 
history, physical examination and ECG. The American college of Cardiology / 
American Heart Association Guidelines Committee later refined and 
incorporated cardiac markers for risk stratification (52). 
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MATERIALS AND METHODS  
 Neopterin is an activation marker for monocytes / macrophages and its 
circulating levels in the Serum is considered to be one of the prognostic 
markers in the treatment of AMI. 
 
INCLUSION CRITERIA 
(1) All cases admitted in the ICCU with the clinical features of AMI and 
with the positive documentation like increased cardiac enzyme levels, 
ECG findings, ECHO findings, etc. 
(2) The group of patients in the age group between 45 – 65 years were 
selected irrespective of the gender difference.   
(3) The associated findings like Hypertension, Diabetes Mellitus and 
Hypercholesterolemia were also included in the study. 
(4) Patients with acute symptoms only were selected irrespective of time of 
admission. 
 
EXCLUSION CRITERIA 
1. Patients with features with Koch’s lesion. 
2. Patients who attended OP with features of atypical chest pain. 
3. Patients with HIV infection. 
4. Patients who underwent renal transplant recently. 
5. Patients with the clinical features of viral infection. 
6. Patients with malignant diseases. 
7. Patients with autoimmune diseases. 
8. Patients who had recent blood transfusion. 
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 The patients who had fulfilled the above criteria were selected for the 
study.  The present study is the estimation of the Serum Neopterin in patients 
with AMI and its short term prognostic significance during hospitalisation. For 
this study the prior permission from the DEAN, Thanjavur Medical College, 
Thanjavur, the Professor and H.O.D, Department of Cardialogy, Thanjavur 
Medical College, Thanjavur and the Associate Professor and H.O.D, 
Department of Biochemistry was obtained. 
 
 To start with the study, a protocol was framed with inclusion, exclusion 
criteria, Aims and objectives, materials and methods and with the review of 
literatures and references taken from various international journals and from 
the prescribed Text books of Cardiology (Harrison’s, Text Book of Medicine,  
Braunwald’s  heart disease). 
 
 For this study 40 patients were selected as study group and 40 patients 
were selected as control group, based on the inclusion / exclusion criteria. 
The study group were collected from the ICCU Department of Cardiology, 
Thanjavur Medical College, Thanjavur.  The blood samples of the study group 
were properly stored in the deep freezer after perfect centrifugation. The 
blood samples of the control group were collected from the normal persons 
and after perfect centrifugation and they were stored in the deep freezer. 
During collection the usual precautions for venipuncture were observed. The 
grossly haemolytic, icteric and lipemic samples were discarded. Samples 
were centrifuged again before assay, to remove any particulate material.  
15 
 
 The Quantitative estimation of Serum Neopterin was done using 
Neopterin ELISA, Enzyme linked Immuno sorbent Assay for the Invitro 
Diagnostic Quantitative Determination of Serum Neopterin, obtained from IBL 
International.  
 
(I) QUANTITATIVE DETERMINATION OF SERUM NEOPTERIN 
 TEST PRINCIPLE: Solid phase Enzyme Linked Immuno Sorbent Assay 
(ELISA) based on the basic principle of a competitive ELISA.  An unknown 
amount of antigen in the sample and a fixed amount of enzyme labelled 
antigen compete for the antibody binding sites (rabbit-anti-neopterin).  Both 
antigen-antibody complexes bind to the wells of the micro titre strips coated 
with a goat-anti-rabbit antibody. Unbound antigen is removed by washing. The 
intensity of the colour developed after the substrate incubation is inversely 
proportional to the amount of antigen in the sample.  
 
MATERIALS SUPPLIED IN THE KIT 
Quantity Symbol Component 
1x 12x 8 MTP Microtiter Plate 
6x0.5ml CAL A-F Standard A-F 
2x0.5ml CONTROL 1+2 Control 1+2 
1x0.1 ml ENZCONJ-CONC Enzyme Conjugate 
1x5ml ANTISERUM Neopterin AntiSerum 
1x17ml TMB SUBS TMB Substrate Solution 
1x17ml TMB STOP TMB Stop Solution 
1x50ml WASH BUF CONC Wash Buffer 
1x18ml ASSAY BUF Assay Buffer 
1x FOIL Adhesive Foil 
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PRE-TEST SETUP INSTRUCTIONS 
(A) Preparation of Lyophilized or Concentrated Components 
Dilute / 
Dissolve Component with Diluents
Relati
on Remarks 
Stor
age 
Stabili
ty 
15ml Wash buffer 285ml Bidist. water 1:20  2-8
0c 1 month 
25 
microliter 
Enzyme 
conjugate 5ml 
Assay 
buffer 1:201 
Store 
Protected 
from 
light 
2-80c 24 hours 
 
TEST PROCEDURE 
MANUAL PROCEDURE 
 1 Pipette 10 µL of each Standard, Control, Serum sample and diluted 
urine sample into the respective wells of the Microtiter Plate. 
2 Pipette 100 µL of  freshly prepared  Enzyme Conjugate (1:201) into 
each well. 
3 Pipette 50 µL of Neopterin AntiSerum into each well. 
4 Cover plate with black adhesive foil. Incubate 90 min at RT 
(18-250C) on an orbital shaker (500 rpm) in the dark. 
5 Remove adhesive foil. Discard incubation solution. Wash plate 4x with 
diluted Wash Buffer. Remove excess solution by tapping the inverted 
plate on a paper towel. 
6 For adding of  Substrate and Stop Solution use, if available, an 
8-channel Micropipettor. Pipetting should be carried out in the same 
time intervals for Substrate and Stop Solution. Use positive 
displacement and avoid formation of air bubbles. 
7 Pipette 150µL of TMB Substrate Solution into each well. 
8 Incubate 10 min at RT(18-250C). 
9 Stop the substrate reaction by adding 150 µL of TMB Stop Solution 
into each well. Briefly mix contents by gently shaking the plate. 
10 Measure optical density with a photometer at 450 nm (Reference-
wavelength600-650 nm) within 15 min. 
 
Normal Range of Serum Neopterin < 10 nmol / lit  
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QUALITY CONTROL FOR SERUM NEOPTERIN 
 
 
 
 
 
 
 
 
 
 
 (II) ESTIMATION OF CKMB 
CKMB (Immuno inhibition / Modified IFCC Method) 
 
Principle 
     CK- M fractions of the CK-MM and the CK-MB in the sample are 
completely inhibited by an anti CK-M antibody present in the reagent. Then 
the activity of the CK-B fraction is measured by the CK(NAC act) method. The 
CK-MB activity is obtained by multiplying the CK-B activity by two. 
 
Reagents Preparation  
Reagents are ready to use  
 Enzyme reagent (L1) 
 Starter reagent (L2) 
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Control  : Reconstitute with 1ml of good quality D.W.Leave for 5 minutes 
to hydrate and mix by swirling to avoid frothing.   The reconstituted control is 
stable for atleast 3 days when stored    
 
Procedure 
 Wavelength / filter                :    340nm 
 Temperature                         :   370 C /300 C/ 250 C 
 Light path                              : 1 cm 
 
Substrate Start Assay 
Pipette into a clean dry test tube labelled Test (T)  
Addition 
Sequence 
(T) 
250C / 300C/ 370C 
Enzyme reagent (L1) 
Sample or Control ( C) 
0.8  ml 
0.05  ml 
Incubate at the assay temperature 
for  5 minutes and add 
Starter Reagent (L2) 0.2 ml 
 
Mix well and read the initial absorbance A0   after 5 minutes and repeat the 
absorbance reading after every 1, 2 & 3 minutes. Calculate the mean 
absorbance. 
Change per minute (   ^A/ min). 
 
Calculations 
 CK-MB activity in U/L  25°C / 30°C / 37°C = ^A / min. x 6666 
 
REFERENCE RANGE 
 Serum CKMB levels up to 24 units/litre at 370C. 
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(III) ESTIMATION OF GLUCOSE  
GLUCOSE OXIDASE PEROXIDASE (GOD/POD) METHOD– MANUAL AND  
AUTOANALYSER METHOD 
 
Principle 
    Glucose is oxidised by glucose oxidase (GOD) to give gluconic acid and 
hydrogen peroxidase. The hydrogen peroxide formed is broken down by 
peroxidase to water and oxygen. The later oxidises phenol which combines 
with 4-aminophenazone to give a red coloured complex. The intensity of the 
red coloured complex is proportional to the concentration of glucose in the 
test. The intensity of the coloured complex is measured colorimetrically at 515 
nm (500-530). 
 
Reagents  
 1) Glucozyme Reagent I  - Enzyme –  chromogen tablets   
 2) Glucozyme Reagent II - Phenol solution   
 3) Glucozyme standard  - 100mg / dl  
 
 
PROCEDURE 
 
Reagents Blank (B) (mL) 
Standard (S) 
( mL) 
Test (T) 
(mL) 
Glucozyme  
working reagent 1 1 1 
Serum or plasma  - - 0.01 
Standard solution - 0.01 - 
Distilled water 0.01 - - 
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 Mix the contents of the test tubes thoroughly, and place at 370C for 15 
minutes. Measure the optical density (OD) of the test and the standard 
against blank at 515 nm (Range 500-530).  The final colour complex is stable 
for more than two hours at room temperature. 
 
CALCULATION 
Stock standard concentration                 = 1000mg% 
Working Standard    = 100mg% 
100mL contains    = 100mg% 
Concentration of the Standard   = 0.01mg% 
 
ACTUAL VOLUME OF BLOOD 
 
 Actual Volume of Blood taken  = 0.01ml 
 
Glucose present in 100mL of plasma / Serum 
                    O.D (T) – O.D (B)  X  conc of std   
         = X 100 
                    O.D (S) – O.D (B)  X  vol of std 
 
 = ்ି஻ 
ௌି஻
 ൈ  ଴.଴ଵ
଴.଴ଵ
   ൈ 100   
 
 = ்ି஻ 
ௌି஻
   ൈ 100 
 
Normal Value 
Fasting Blood Glucose    -     80 – 120 mgs/ dl. 
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(IV) ESTIMATION OF TOTAL CHOLESTEROL 
 The test is performed in the reagent kit by Enzymatic cholesterol 
esterase method.  
 
PRINCIPLE:  The free cholesterol liberated from the cholesterol esters by 
cholesterol esterase is oxidised by cholesterol oxidase to Cholesterol-4-en-3-
one with the simultaneous production of hydrogen per oxide. The hydrogen 
per oxide reacts with 4-amino anti pyrine and a phenolic compound in the 
presence of peroxidase to yield a red coloured complex.  
                                              
                                        cholesterol esterase 
Cholesterol Ester + H2O                           Cholesterol+ Fatty acids 
Cholesterol +O2     cholesterol oxidase   Cholesterol-4-en-3-one + H2O2 
2H2O2  + phenol+4- Aminoantipyrene        peroxidise       Red quinone+ 4H2O. 
 
The concentration of cholesterol in the sample is directly proportional to the 
intensity of the red complex (Red Quinone) which is measured at 500nm. 
 
REAGENTS 
Reagent 1 (Enzymes/ Chromogen) 
Cholesterol Esterase                      ≥ 30U/L 
Cholesterol Oxidase                       ≥ 250U/L 
Peroxidase                                 ≥ 1000U/L 
4-Aminoantipyrine           0.5mmol/L 
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Reagent 1A (Buffer) 
Pipes buffer, pH 6.95                50mmol/L 
Phenol                              24mmol/L 
Sodium Cholate          0.5mmol/L 
Standard (Cholesterol 200 mg/dL) 
Cholesterol                              2g /L 
 
Reagent Reconstitution  
 Allow the reagents to attain room temperature.   Dissolve the contents of 
one bottle of reagent 1 with one bottle of reagent 1A.  Mix by gentle swirling.  
 
Dispense into test tubes 
 Blank Standard Test 
Reconstituted Reagent 1 mL 1 mL 1 mL 
Standard - 10 µL - 
Sample - - 10 µL 
  
Incubate for 5 minutes at 370C. Mix and read at 500nm. 
  
Normal value 
 
<200 mgs/dl 
 
 
 (V)  ACCUCARE 
TRIGLYCERIDES-SLR 
METHOD 
 Enzymatic colorimetric test 
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PRINCIPLE 
 Triglycerides are determined after enzymatic hydrolysis with lipases. The 
quinonemine indicator is formed from hydrogen peroxide, 4-aminophenazone 
and 4-chlorophenol under the catalytic influence of per oxidase.  
 
REAGENTS 
 Reagent I            :   Enzyme reagent 
 Triglyceride Standard      : 200mg/dl  
 
SAMPLE 
 Serum, heparinised plasma or EDTA plasma. 
 
STABILITY 
 3 days at 2- 80C. 3 months at-200C. 
 
REAGENT PREPARATION   
 Reagent is ready to use. 
 
MANUAL PROCEDURE 
 Pipette into Test Tubes 
 
 Blank Std Sample 
Sample _ _ 10µl 
Standard _ 10 µl _ 
Reagent 1000 µl 1000 µl 1000 µl 
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Mix well, incubate for 5 minutes, at 37 0 C (or 10 minutes at 20-250 C). 
Measure absorbance of Sample (AT) and Standard (AS) against reagent 
blank at 505 nm.   The colour is stable for 30 minutes at  20-  250 C. 
 
CALCULATION AND LINEARITY   
  
AT /AS x conc. Std = mg / dl   Triglycerides 
 
 
This method is linear upto concentration of 1300 mg/dl. Dilute samples above 
this  concentration  1 : 1  with 0.9% saline   and   reassay.  Multiply the result 
by two. 
 
REFERENCE   VALUES  
Men   :    60  -  165   mg / dl 
Women  :    40  - 140  mg  / dl 
 
(VI)  ESTIMATION OF HDL - CHOLESTEROL 
PHOSPHOTUNGSTATE METHOD 
PRINCIPLE 
 Chylomicrons, VLDL (Very Low Density Lipoproteins) and LDL  
Fractions  in  Serum  or  plasma   are  separated  from  HDL by precipitating 
with  phosphotungstic  acid  and  magnesium  chloride.  After  centrifugation,  
the   cholesterol  in  the  HDL  fraction, which  remains  in  the  supernatant is  
assayed  with  enzymatic  cholesterol method,  using  Cholesterol  esterase, 
Cholesterol Oxidase, Peroxidase  and  chromogen  4-Aminoantipyrine / 
Phenol. 
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REAGENTS 
Reagent 1 (Enzymes / Chromogens) 
 Cholesterol Esterase  ≥ 30 U /L 
 Cholesterol Oxidase  ≥250 U /L 
 Peroxidase    ≥ 1000U /L 
 4- Aminoantipyrine   0.5 mmol / L 
Reagent 1 A (Buffer) 
 Pipes buffer, pH 6.95  50 mmol/ L 
 Phenol    24 mmol / L 
 Sodium Cholate   0.5 mmol / L 
Reagent 2 (Precipitating Reagent)  
 Phosphotungstic Acid    2.4 mmol / L 
 Magnesium Chloride  39 mmol / L 
Standard (HDL Cholesterol 50 mg / dL) 
 Cholesterol    0.5 g / L 
REAGENT RECONSTITUTION 
  Allow the reagents to attain room temperature.  Dissolve the contents 
of one bottle of reagent 1 into one bottle of reagent 1A. Mix by gentle swirling 
till completely dissolved. Write the Reconstitution Date in the space provided 
on the label of bottle 1 A.   Wait for 5 minutes before using. 
PROCEDURE 
  The samples, the precipitating reagent 2 and the reconstituted reagent 
should be brought to room temperature prior to use. 
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1. PRECIPITATION 
Dispense into Centrifuge Tube 
 Test 
Sample 0.20 mL ( 200µ L) 
Precipitating Reagent 2 0.20 mL (200µ L) 
 
Mix  well. 
 Centrifuge at 1500 g or 3500 -4000rpm for 10 minutes.  Separate the 
clear supernatant immediately and determine the cholesterol content as given 
below.  
HDL Cholesterol standard is not subjected to the precipitation step.   
Dispense into test tubes. 
 Blank Standard Test 
Reconstituted Reagent 1ml 1ml 1ml 
Standard - 20µl - 
Supernatant - - 20µl 
 
Incubate for 5 minutes at 370C. Mix and read. 
Reference Value:  30- 70 mg /dl. 
 
CALCULATED PARAMETERS 
(VII)  Freidwald’s Formula :                                                                                        
         Very Low Density Lipoprotein:    =      
tryacylglycerol
5
  
 
(VIII) Low Density Lipoprotein        =      Total cholesterol –  [HDL+VLDL]     
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RESULTS & DISCUSSION  
Age Matched Statistical Analysis between the study group and the 
control group age less than 45 years 
 
Table  No. 1.  T-Test 
Sl. 
No Group Mean Std. Deviation Statistical inference 
1 BP1   T = .352 
P > 0.05 
Not Significant 
 Test (n=3) 136.67 30.551 
 Control (n=4) 130.00 20.000 
2 BP2   T = .849 
P > 0.05 
Not Significant 
 Test (n=3) 90.67 4.163 
 Control (n=4) 85.50 9.713 
3 FBG   T = 1.081 
P > 0.05 
Not Significant 
 Test (n=3) 119.33 37.541 
 Control (n=4) 99.50 4.726 
4 CK_MB   T = 5.300 
P < 0.05 
Significant 
 Test (n=3) 45.33 10.066 
 Control (n=4) 16.50 4.123 
5 N   T = 2.319 
P > 0.05 
Not Significant 
 Test (n=3) 22.57 13.568 
 Control (n=4) 7.21 1.635 
6 PH   T = 2.390 
P > 0.05 
Not Significant 
 Test (n=3) 3.67 .577 
 Control (n=4) 3.00 .000 
7 MACE   T = 2.390 
P > 0.05 
Not Significant 
 Test (n=3) 3.67 .577
 Control (n=4) 3.00 .000 
8 D   T = 2.390 
P > 0.05 
Not Significant 
 Test (n=3) 3.67 .577 
 Control (n=4) 3.00 .000 
9 SR.CHOLE   T = 3.353 
P > 0.05 
Not Significant 
 Test (n=3) 193.33 17.898 
 Control (n=4) 153.50 13.772 
10 TGL   T = -.374 
P > 0.05 
Not Significant 
 Test (n=3) 125.00 6.557 
 Control (n=4) 128.00 12.463 
11 HDL   T = -1.036 
P > 0.05 
Not Significant 
 Test (n=3) 36.00 12.490 
 Control (n=4) 46.00 12.728 
12 LDL   T = 3.166 
P > 0.05 
Not Significant 
 Test (n=3) 132.33 16.773 
 Control (n=4) 76.25 26.625 
13 VLDL   T = -.319 
P > 0.05 
Not Significant 
 Test (n=3) 25.00 1.000 
 Control (n=4) 25.50 2.517 
Df = 5 
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Age Matched Statistical Analysis between the study group and the 
control group age less than 45 years 
 
 From the data illustrated in the Table No. 1 age matched statistical 
analysis between the study group and the control group of age less than             
45 years is analysed.   The following results are obtained as the statistical 
outcome.  The parameters are analysed between the study and the control 
group.  Among the parameters, there is a significant difference in the levels of 
CKMB (P Value < 0.05) which is statistically significant.  
 
 The other para meters between the study and the control group are not 
showing statistically significant difference.       
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Age Matched Statistical Analysis between the study group and the 
control group age between 45 to 55 years 
Table No. 2.  
T-Test 
Sl. 
no Group Mean S.D Statistical inference 
1 BP1   T = .822 
P > 0.05 
Not Significant  
 Test (n=13) 130.31 17.997 
 Control (n=18) 125.44 14.901 
2 BP2   T = .952 
P > 0.05 
Not Significant  
 Test (n=13) 85.85 9.881 
 Control (n=18) 83.11 6.106 
3 FBG   T = .451 
P > 0.05 
Not Significant  
 Test (n=13) 113.38 27.488 
 Control (n=18) 109.11 24.916 
4 CK_MB   T = 5.445 
P < 0.05 
Significant  
 Test (n=13) 47.15 21.575 
 Control (n=18) 18.67 4.887
5 N  T = 4.726 
P < 0.05 
Significant 
 Test (n=13) 37.55 28.227 
 Control (n=18) 6.28 1.160 
6 PH   T = 5.191 
P < 0.05 
Significant  
 Test (n=13) 3.62 .506 
 Control (n=18) 3.00 .000 
7 MACE T = 6.155 
P < 0.05 
Significant  
 Test (n=13) 3.69 .480 
 Control (n=18) 3.00 .000 
8 D   T = 3.799 
P < 0.05 
Significant  
 Test (n=13) 3.46 .519 
 Control (n=18) 3.00 .000 
9 Sr.chole    T = 5.028 
P < 0.05 
Significant  
 Test (n=13) 213.08 32.607 
 Control (n=18) 166.83 18.402 
10 TGL   T = -1.087 
P > 0.05 
Not Significant  
 Test (n=13) 121.00 12.281 
 Control (n=18) 128.22 21.493 
11 HDL    T = -4.881 
P < 0.05 
Significant  
 Test (n=13) 34.31 7.005 
 Control (n=18) 47.89 8.065 
12 LDL   T = 6.073 
P < 0.05 
Significant  
 Test (n=13) 154.46 34.452 
 Control (n=18) 93.50 21.443 
13 VLDL   T = -.927 
P > 0.05 
Not Significant  
 Test (n=13) 24.15 2.609 
 Control (n=18) 25.44 4.488 
Df = 29 
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Age Matched Statistical Analysis between the study group and the 
control group age between 45 - 55 years 
 
 From the Table No. 2. the data illustrated is the statistical analysis 
between the study group and the control group.  In the age group of between 
45 to 55 years.  It is clear that the Serum levels of CKMB, Neopterin, 
Cholesterol, HDL, LDL are having statistically significant difference between 
the 2 groups at the P level  P<0.05 significant.  
 
 The parameters like systolic Blood Pressure, diastolic blood pressure, 
FBG are not having significant difference between the two groups. 
 P Value more than 0.05 not significant.  
 The parameters like History of previous hospitalisation, MACE and 
death are having significant difference between the two groups  
 P Value less than 0.05 significant.  
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Age Matched Statistical Analysis between the study group and the 
control group age more than 55 years 
Table No. 3.  
T-Test 
Sl.  
No Group Mean S.D Statistical inference 
1 BP1   T = .211 
P > 0.05 
Not Significant 
 Test (n=24) 127.00 22.341 
 Control (n=18) 125.78 11.680 
2 BP2   T = .000 
P > 0.05 
Not Significant 
 Test (n=24) 83.67 9.898 
 Control (n=18) 83.67 7.236 
3 FBG   T = .116 
P > 0.05 
Not Significant 
 Test (n=24) 106.42 19.675 
 Control (n=18) 105.61 25.435 
4 CK_MB   T = 2.405 
P > 0.05 
Not Significant 
 Test (n=24) 41.33 21.902 
 Control (n=18) 26.28 17.306 
5 N   T = 5.846 
P < 0.05 
Significant 
 Test (n=24) 25.68 13.413 
 Control (n=18) 7.05 1.551 
6 PH   T = 2.124 
P > 0.05 
Not Significant 
 Test (n=24) 3.21 .415
 Control (n=18) 3.00 .000 
7 MACE   T = 4.140 
P < 0.05 
Significant 
 Test (n=24) 3.50 .511 
 Control (n=18) 3.00 .000 
8 D   T = 2.124 
P > 0.05 
Not Significant 
 Test (n=24) 3.21 .415 
 Control (n=18) 3.00 .000
9 SR.CHOLE   T = 4.891 
P < 0.05 
Significant 
 Test (n=24) 213.63 40.858 
 Control (n=18) 163.39 17.161 
10 TGL   T = .659 
P > 0.05 
Not Significant 
 Test (n=24) 135.08 18.606 
 Control (n=18) 130.28 28.617 
11 HDL   T = -3.026 
P < 0.05 
Significant 
 Test (n=24) 34.83 9.361 
 Control (n=18) 43.33 8.506 
12 LDL   T = 6.198 
P < 0.05 
Significant 
 Test (n=24) 151.71 36.901 
 Control (n=18) 92.22 19.681 
13 VLDL   T = .745 
P > 0.05 
Not Significant 
 Test (n=24) 27.08 3.647 
 Control (n=18) 26.00 5.760 
Df=40 
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Age Matched Statistical Analysis between the study group and the 
control group age more than 55 years 
 
 
 From the Table 3. the data obtained is the age matched  Statistical 
Analysis between the study group and the control group of age more than 55 
years. 
 
 From the table is clear that there is statistically significant difference 
between the study and the control groups for the following parameters like 
Serum Neopterin, MACE, Serum cholesterol, HDL. LDL.  
 
 The P value Less than 0.05 significant  
    
 The statistical difference with the other parameters like systolic blood 
pressure, diastolic blood pressure, FBG, CKMB, pH, Death, TGL and VLDL is 
not significant.  
 
 P value more than 0.05.   
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Sex Matched Statistical Analysis between the study group and the 
control group  
Females 
Table No. 4.  
T-Test 
Sl.  
No Group Mean S.D Statistical inference 
1 BP1   T = -.071 
P > 0.05 
Not Significant 
 Test (n=12) 120.33 20.535 
 Control (n=13) 120.77 7.981 
2 BP2 T = -.034 
P > 0.05 
Not Significant 
 Test (n=12) 80.67 10.491 
 Control (n=13) 80.77 3.113 
3 FBG   T = -.387 
P > 0.05 
Not Significant 
 Test (n=12) 105.67 20.214 
 Control (n=13) 109.54 28.637 
4 CK_MB T = 5.429 
P < 0.05 
Significant 
 Test (n=12) 52.75 21.730 
 Control (n=13) 19.08 5.220 
5 N   T = 5.268 
P < 0.05 
Significant 
 Test (n=12) 21.57 10.015 
 Control (n=13) 6.80 1.427 
6 PH   T = 1.547 
P > 0.05 
Not Significant 
 Test (n=12) 3.17 .389 
 Control (n=13) 3.00 .000 
7 MACE   T = 2.445 
P > 0.05 
Not Significant 
 Test (n=12) 3.33 .492 
 Control (n=13) 3.00 .000 
8 D   T = 1.547 
P > 0.05 
Not Significant 
 Test (n=12) 3.17 .389 
 Control (n=13) 3.00 .000 
9 SR.CHOLE   T = 4.497 
P < 0.05 
Significant 
 Test (n=12) 222.83 44.315 
 Control (n=13) 164.00 15.722 
10 TGL   T = 1.022 
P > 0.05 
Not Significant 
 Test (n=12) 136.42 21.177 
 Control (n=13) 125.62 30.426 
11 HDL   T = -3.595 
P < 0.05 
Significant 
 Test (n=12) 33.08 10.689 
 Control (n=13) 46.23 7.429 
12 LDL   T = 5.743 
P < 0.05 
Significant 
 Test (n=12) 162.33 40.708 
 Control (n=13) 89.38 20.271 
13 VLDL T = 1.011 
P > 0.05 
Not Significant 
 Test (n=12) 27.33 4.141 
 Control (n=13) 25.23 6.002 
Df = 23 
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Sex Matched Statistical Analysis between the study group and the 
control group  
Females 
 From the Table No. 4 Sex Matched Statistical Analysis between the 
study group and the control group in the Females is obtained.  
 
 It is clear from the data that the parameters like CKMB level, Serum 
Neopterin level, Serum Cholesterol, HDL and LDL are having statistically 
significant difference between the control and the study groups.  
 
 P Value Less than 0.05 significant.  
 
 The other parameters like systolic blood pressure, diastolic blood 
pressure, FBG, history of previous hospitalisation, Death, TGL and VLDL are 
not showing statistically significant difference.  
         
 P Value more than 0.05 not significant. 
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Sex Matched Statistical Analysis between the study group and the 
control group  (Males) 
Table No. 5. 
T-Test 
Sl. No. Group Mean S.D Statistical inference
1 BP1   T = .778 
P > 0.05 
Not Significant 
 Test (n=28) 132.43 20.780 
 Control (n=27) 128.59 15.270 
2 BP2   T = .783 
P > 0.05 
Not Significant 
 Test (n=28) 86.71 8.798 
 Control (n=27) 84.96 7.733 
3 FBG   T = .990 
P > 0.05 
Not Significant 
 Test (n=28) 111.36 24.897 
 Control (n=27) 105.15 21.431 
4 CK_MB   T = 3.469 
P < 0.05 
Significant 
 Test (n=28) 39.57 19.687 
 Control (n=27) 23.22 14.833 
5 N   T = 6.065 
P < 0.05 
Significant 
 Test (n=28) 32.62 22.172 
 Control (n=27) 6.68 1.436 
6 PH   T = 4.749 
P < 0.05 
Significant 
 Test (n=28) 3.46 .508 
 Control (n=27) 3.00 .000 
7 MACE   T = 7.411 
P < 0.05 
Significant 
 Test (n=28) 3.68 .476 
 Control (n=27) 3.00 .000 
8 D   T = 4.103 
P < 0.05 
Significant 
 Test (n=28) 3.39 .497 
 Control (n=27) 3.00 .000 
9 SR.CHOLE   T = 5.980 
P < 0.05 
Significant 
 Test (n=28) 207.25 32.929 
 Control (n=27) 163.93 18.562 
10 TGL   T = -.816 
P > 0.05 
Not Significant 
 Test (n=28) 126.89 14.793 
 Control (n=27) 130.81 20.511 
11 HDL   T = -4.249 
P < 0.05 
Significant 
 Test (n=28) 35.46 7.743 
 Control (n=27) 45.37 9.487 
12 LDL   T = 7.371 
P < 0.05 
Significant 
 Test (n=28) 146.36 31.602 
 Control (n=27) 92.07 21.963 
13 VLDL   T = -.530 
P > 0.05 
Not Significant 
 Test (n=28) 25.39 3.010 
 Control (n=27) 25.93 4.349 
Df = 53 
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Sex Matched Statistical Analysis between the study group and the 
control group  
Males  
 From the Table No. 5 the data obtained is Sex Matched Statistical 
Analysis between the study group and the control group in males.  
 From the data it is clear that the parameters like CKMB, Serum 
Neopterin, MACE, history of previous Hospitalisation, Death, Serum 
Cholesterol, HDL and LDL are having statistically significant difference 
between the control and test groups.  
 P Value  less than 0.05 significant  (P < 0.05) 
 The other parameters like systolic blood pressure, diastolic blood 
pressure, FBG, TGL, VLDL are not showing statistically significant difference 
between control and the test group.  
 P Value more than 0.05 not significant.  (P < 0.05) 
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Independent Samples Test for Serum Neopterin Level between the 
control and the test group 
 
Table No. 6. 
Group Statistics 
 
 
Group N Mean Std. Deviation Std. Error Mean 
N 
Test 40 29.30 19.873 3.142 
Control 40 6.72 1.416 .224 
 
Independent Samples Test 
 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. t df 
Sig. 
(2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% 
Confidence 
Interval of the 
Difference 
Lower Upper 
N 
Equal variances assumed 23.181 .000 7.170 78 .000 22.59 3.150 16.315 28.858 
Equal variances not 
assumed   7.170 39.396 .000 22.59 3.150 16.216 28.956 
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Independent Samples Test for Serum Neopterin Level between the 
control and the test group  
 
 
 From the table No. 6 the results obtained is the independent sample 
test between the study and the control group with respect to the levels of 
Serum Neopterin.    
 
 The results obtained show that there is statistically highly significant 
difference between the study and the control group with respect to the Serum 
Neopterin levels. 
 
 0.000 Less than 0.05 less than P sig. 2 tailed.  
 
 Highly Significant.     
 
 (P < 0.000 < 0.05) 
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One Sample statistical analysis in the study group between Serum 
CKMB and Serum Neopterin Level  
 
Table No. 7.  
T-Test 
One-Sample Statistics 
 N Mean Std. Deviation Std. Error Mean 
Neopterin 40 1.95 .221 .035 
CK_MB 40 1.78 .423 .067 
 
One-Sample Test 
 
 
Test Value = 25 
t df Sig. (2-tailed) 
Mean 
Difference 
95% Confidence Interval of the 
Difference 
Lower Upper 
Neopterin -660.475 39 .000 -23.05 -23.12 -22.98 
CK_MB -347.333 39 .000 -23.23 -23.36 -23.09 
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One Sample statistical analysis in the study group between Serum 
CKMB and Serum Neopterin Level 
 
 
 From the Table No. 7. One Sample statistical analysis in the study 
group between Serum CKMB and Serum Neopterin Level 
 
 The results obtained show that there is significant statistical difference 
is found in the study group between Serum Neopterin levels and the Serum 
CKMB levels. 
 
 0.000 less than 0.05 less than P Value  
 
 Highly Significant       
 (P < 0.000 < 0.05) 
 CKMB – Highly Significant in the study group with respect to Serum 
Neopterin Level.    
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Chi-Square Test 
Neopterin morethan 25 *MACE Cross tabulation  
Study Group  
Table No. 8.  
Crosstabs 
Case Processing Summary 
 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
N25 * MACE 40 100.0% 0 .0% 40 100.0% 
 
N25 * MACE Cross tabulation 
 
 
MACE 
Total 
Negative Positive  
N25 
Less 25 
Count 17 1 18 
% within N25 94.4% 5.6% 100.0% 
More 25 
Count  22 22 
% within N25  100.0% 100.0% 
Total 
Count 17 23 40 
% within N25 42.5% 57.5% 100.0% 
 
Chi-Square Tests 
 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig.  
(1-sided) 
Pearson Chi-Square 36.135(b) 1 .000   
Continuity Correction(a) 32.374 1 .000   
Likelihood Ratio 46.824 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 35.232 1 .000   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.65. 
42 
 
Chi-Square Test 
Neopterin morethan 25 *MACE Cross tabulation  
Study Group  
 
 From the Table No. 8. the data obtained is Chi-Square Test analysis 
between the Serum Neopterin levels more than 25 nmol/lit. and its association 
with MACE in the study group.   
 
 The statistical inference obtained in the study group proves that there 
is statistically highly significant association between the Serum Neopterin 
levels more than 25 nmol/lit and the occurrence of the MACE.  
 
 0.000 Less than 0.05 Less than P Value.  
 
 Highly Significant association between Serum Neopterin and MACE in 
the study group.  
 
 (P < 0.000 < 0.05) 
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Chi-Square Test 
Neopterin morethan 25  *Death Cross tabulation 
Study Group 
Table No. 9.  
Crosstabs 
Case Processing Summary 
 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
N25 * D 40 100.0% 0 .0% 40 100.0% 
 
N25 * D Crosstabulation 
 
 
D 
Total 
Negative Positive 
N25 
Less 25 
Count 18  18 
% within N25 100.0%  100.0% 
More 25 
Count 9 13 22 
% within N25 40.9% 59.1% 100.0% 
Total 
Count 27 13 40 
% within N25 67.5% 32.5% 100.0% 
 
Chi-Square Tests 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 15.758(b) 1 .000   
Continuity Correction(a) 13.179 1 .000   
Likelihood Ratio 20.679 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 15.364 1 .000   
N of Valid Cases 40     
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.85. 
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Chi-Square Test 
Neopterin morethan 25  *Death Cross tabulation  
Study Group  
 
 From the Table No. 9 the result obtained is the Chi-Square Test 
analysis in the study group with respect to Serum Levels of Neopterin more 
than 25 nmol/lit and the occurrence of death in the study group.  
 The statistical inference is there is highly significant association 
between the Serum levels more than 25nmol/lit  and the occurrence of death 
in the study group.  
 0.000 less than 0.05 less P value    
Highly significant association between the high levels of Serum Neopterin and 
the occurrence of the Death.  
 (P < 0.000 < 0.05) 
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Chi-Square Test 
N10 *Blood Pressure Cross tabulation  
Study Group 
Table No. 10.  
N1 * BP1G systolic  
Sl. 
No Nepterin 
BP1G 
Statistical inferenceBelow 120 
(n=23) 
above 120 
 (n=17) 
1 Below10 1 (50%) 1 (50%) X
2=.048 
Df =1 
P < 0.05 
Significant 2 
more 
than 10 22 (57.9%) 16 (42.1%) 
 
 
 
Diastolic  
Sl. 
No Nepterin 
BP2G 
Statistical inferenceBelow 80 (n=19) above 80 (n=21) 
1 Below10 1 (50%) 1 (50% X
2=.005 
Df =1 
P < 0.05 
Significant 2 
more 
than 10 18 (47.4%) 20 (52.6%) 
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Chi-Square Test 
N10 *Blood Pressure Cross tabulation  
Study Group 
 From Table No. 10 the data obtained is the Chi-square test analysis 
between the systolic blood pressure more than 120 mm of Hg. and its 
association with Serum Neopterin Levels more than 10nmol/lit.  
 The results show that there is significant association between the 
systolic blood pressure and the Serum Neopertin levels more than                 
10nmol / lit.    
P Less than 0.05 significant. 
 From the same table the association between the diastolic blood 
pressure more than 80mm of Hg. and the Serum Neopertin levels more than 
10nmol/lit is obtained and it is found that the association between the two is 
significant.  
P Less than 0.05 significant. 
There is significant association between the Serum Neopertin and the 
Hypertension.  
 (P < 0.000 < 0.05) 
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SPEARMAN’S CORRELATIONS  
Table No. 11.  
  AGE  SEX  N  BP1 BP2 FBG CK_MB PH MACE  D SR.CHOLE TGL HDL LDL VLDL 
AGE  1  .344(*)  ‐.178  ‐.165 ‐.234 ‐.058 ‐.146 ‐.406(**) ‐.253  ‐.311 .217 .322(*) .109 .185 .334(*) 
SEX  .344(*)  1  ‐.279  ‐.325(*) ‐.347(*) ‐.092 .317(*) ‐.282 ‐.320(*)  ‐.221 .158 .218 ‐.152 .248 .211 
N  ‐.178  ‐.279  1  .315(*) .363(*) .224 ‐.312 .707(**) .857(**)  .735(**) ‐.270 ‐.132 ‐.081 ‐.286 ‐.117 
BP1  ‐.165  ‐.325(*)  .315(*)  1  .878(**) .079 ‐.254 .194 .230  .299 ‐.283 ‐.117 .036 ‐.359(*) ‐.125 
BP2  ‐.234  ‐.347(*)  .363(*)  .878(**) 1 .129 ‐.259 .324(*) .234  .356(*) ‐.351(*) ‐.113 ‐.035 ‐.399(*) ‐.116 
FBG  ‐.058  ‐.092  .224  .079 .129 1 ‐.102 .166 .242  .332(*) ‐.195 ‐.237 .058 ‐.162 ‐.235 
CK_MB  ‐.146  .317(*)  ‐.312  ‐.254 ‐.259 ‐.102 1 ‐.056 ‐.127  ‐.222 .030 .038 .075 .012 .031 
PH  ‐.406(**)  ‐.282  .707(**)  .194 .324(*) .166 ‐.056 1 .666(**)  .565(**) ‐.271 ‐.103 ‐.056 ‐.313(*) ‐.109 
MACE  ‐.253  ‐.320(*)  .857(**)  .230 .234 .242 ‐.127 .666(**) 1  .597(**) ‐.287 ‐.138 ‐.031 ‐.313(*) ‐.138 
D  ‐.311  ‐.221  .735(**)  .299 .356(*) .332(*) ‐.222 .565(**) .597(**)  1 ‐.433(**) ‐.303 ‐.028 ‐.423(**) ‐.279 
SR.CHOLE  .217  .158  ‐.270  ‐.283 ‐.351(*) ‐.195 .030 ‐.271 ‐.287  ‐.433(**) 1 .154 .254 .956(**) .210 
TGL  .322(*)  .218  ‐.132  ‐.117 ‐.113 ‐.237 .038 ‐.103 ‐.138  ‐.303 .154 1 ‐.331(*) .106 .982(**) 
HDL  .109  ‐.152  ‐.081  .036 ‐.035 .058 .075 ‐.056 ‐.031  ‐.028 .254 ‐.331(*) 1 .065 ‐.287 
LDL  .185  .248  ‐.286  ‐.359(*) ‐.399(*) ‐.162 .012 ‐.313(*) ‐.313(*)  ‐.423(**) .956(**) .106 .065 1 .158 
VLDL  .334(*)  .211  ‐.117  ‐.125 ‐.116 ‐.235 .031 ‐.109 ‐.138  ‐.279 .210 .982(**) ‐.287 .158 1 
n  40  40  40  40  40 40 40 40 40  40 40 40 40 40 40 
* Correlation is significant at the .05 level (2‐tailed). 
** Correlation is significant at the .01 level (2‐tailed). 
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SPEARMAN’S CORRELATIONS  
 
 From Table No. 11 the Spearman’s Correlations are statistically 
analysed between the Serum Neopterin levels more than 10nmol/lit and the 
various parameters taken for the study.  
 The Serum Neopterin level more than 10 nmol/lit is having statistically 
highly significant relationship with the parameters like MACE, Death and the 
history of previous hospitalisation at the level 0.01 level (2 tailed) Highly 
Significant.  
 The Serum Neopterin level more than 10nmol/lit is having statistically 
significant relationship with blood pressure (both systolic and diastolic) at 0.05 
level significant.  
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TABLE NO. 12.  
FREQUENCY TABLE FOR AGE GROUP  
 
Age Group Frequency Percent 
Valid 
Below 45 Years 3 7.5 
46 – 55 Years 13 32.5 
56 & Above 24 60.0 
 Total 40 100.0 
 
 60% of patients are in the age group of more than 56 years.  
 32.5% of Patients are in the age group of 46 – 55 years.  
 7.5% of Patients are in the age group of below 45 years.  
 
 From the above data around 60% (ie) large group of AMI Patients are 
in the age group of more than 56 years.  This data justifies that AMI 
occurrence is directly proportional to the increase in age group.   
 
AMI  α  INCREASE AGE 
 
 This proves that as age advances the frequency of AMI occurrence is 
higher.    
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TABLE NO. 13.  
FREQUENCY TABLE FOR SEX 
 
Sex Frequency Percent 
Valid 
Male  28 70.0 
Female  12 30.0 
 Total 40 100.0 
 
 From the table 70% of Patients are found to be males.  
 30% of Patients are found to be female.  
 From the data it is evident that Males are having high risk and more 
prone for AMI then females.  
 It is justified that the occurrence of AMI is more common in males than 
the females.  
Occurrence of AMI in Male  >   Occurrence of AMI in Female 
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TABLE NO. 14.  
FREQUENCY TABLE FOR SYSTOLIC BLOOD PRESSURE  
 
BP (Systolic)  Frequency Percent 
Valid 
Below 120  23 57.5 
Above 120  17 42.5 
 Total 40 100.0 
 
 From the above Table 57.5% (23 patients) are having systolic Blood 
pressure below 120mm of Hg. 
 42.5% (17 Patients) are having systolic Blood Pressure more than 120.  
 According to the data the systolic blood pressure does not have any 
significant influence over AMI occurrence.  
 According to the previous studies there is no significant correlation 
between a systolic blood pressure and the occurrence of AMI.  
 The table justifies that there is no influence of the systolic blood 
pressure on the occurrence of AMI.    
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TABLE NO. 15.  
FREQUENCY TABLE FOR DIASTOLIC BLOOD PRESSURE  
 
BP (Diastole)  Frequency Percent 
Valid 
Below 80 19 47.5 
Above 80 21 52.5 
 Total 40 100.0 
 
 
 From the above table it is evident 52.5% (21 patients) are having 
diastolic Blood Pressure above 80mm of Hg. 
 47.5% (19 Patients) are having diastolic Blood Pressure less than 
80mm of Hg.  
 From Table it is evident that there is significant correlation between the 
diastolic Blood Pressure and the occurrence of AMI.  More than 50% of 
patients are having diastolic Blood Pressure above normal.    
 From the table it is justified that the diastolic blood pressure is having 
influence on the occurrence of AMI.  
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TABLE NO. 16. 
FREQUENCY TABLE FOR FBG 
 
FBG Frequency Percent 
Valid 
Below 120 29 72.5 
Above 120 11 27.5 
 Total 40 100.0 
 
 
 From the table it is noted 72.5% (29 patients) are having fasting blood 
sugar below 120 and 27.5% (11 patients) are having fasting blood 
glucose more than 120.  
 
 From the table it is evident that the FBG does not influence the 
occurrence of AMI.   
 According to the data around more than 70% of patients who had AMI 
are showing FBG within normal limits and around 27% of patients with AMI 
are having abnormal FBG.  
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TABLE NO. 17. 
FREQUENCY TABLE FOR CKMB 
 
CKMB Frequency Percent 
Valid 
Less than 25 9 22.5 
More than 25  31 77.5 
 Total 40 100.0 
 
 
 From the table 77.5% (31 patients) are having CKMB levels more than 
25, 22.5% (9 Patients) are having CKMB levels less than 25.    
 From the above table it is clear that the levels of CKMB are increased 
in around 77.5% of patients with AMI and around 22.5% of patients with AMI 
are having CKMB levels within normal limits.  
 This data justifies there is proportionate increase in the Serum level of 
CKMB in patients with AMI.    
 Serum levels of CKMB is having influence on the occurrence of AMI.  
 
 Serum levels of CKMB α AMI.   
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TABLE NO. 18. 
FREQUENCY TABLE FOR NEOPTERIN   
 
Neopterin  Frequency Percent 
Valid 
Below 10 2 5.0 
Above 10 38 95.0 
 Total 40 100.0 
 
 From the above table 95% of patients (38 patients) are having Serum 
Neopterin level more than 10.  
 5% of patients (2 patients) are having Serum Neopterin level            
less than 10.  
 From the above table it is evident that Serum Neopterin level are more 
than normal in around 95% of patients with AMI and only 5% of patients is 
within normal limits.    
 This justifies that there is highly significant correlation between Serum 
Neopterin and the occurrence of AMI.  
 Serum Neopterin  α  AMI. 
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TABLE NO. 19. 
FREQUENCY TABLE FOR PREVIOUS HOSPITALISATION  
 
Previous 
Hospitalisation Frequency Percent 
Valid 
Negative  25 62.5 
Positive  15 37.5 
 Total 40 100.0 
 
 
 From the above table it is noted 62.5% (25 patients) are presented with 
previous history of hospitalisation. 
 
 37.5% (15 patients) are not presented with previous history of 
hospitalisation.  
 
 From the above table it is evident that there is no proportionate 
correlation between the occurrence of AMI and the previous history of 
hospitalisation.    
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TABLE NO. 20. 
FREQUENCY TABLE FOR MACE 
 
MACE Frequency Percent 
Valid 
Negative  17 42.5 
Positive  23 57.5 
 Total 40 100.0 
 
 From the above illustration 57.5% (23 patients) are having ‘B’ response 
(+)  
 42.5% (17 patients) are in the A response (–)  
  
 From the above table it is clear that the occurrences of MACE is 
associated in more than 50% of patients with AMI and around less than 50% 
of patients are not associated with MACE with AMI.    
 From this it is justified that the occurrence of the MACE has significant 
correlation in patients with AMI.    
 MACE   α  AMI  
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TABLE NO. 21. 
FREQUENCY TABLE FOR DEATH 
 
Death  Frequency Percent 
Valid 
Negative  27 67.5 
Positive  13 32.5 
 Total 40 100.0 
 
 From the above table it is found 67.5% (27 Patients) are in the A 
response 32.5% (13 patients) are in the B response.  
 
 From the above table the mortality rate in patient with AMI is less than 
50% that is around 32.5% of patients and the remaining 67.5% of patients are 
discharged without mortality.  The mortality rate can further be reduced by 
early detection and intervention of MACE during hospitalisation.      
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TABLE NO. 22. 
FREQUENCY TABLE FOR SERUM CHOLESTEROL  
 
Serum Cholesterol   Frequency Percent 
Valid 
Less than 200 15 38% 
More than 200 25 62% 
 Total 40 100.0 
 
 
 From the table it is evident that more than 50% of patients with AMI are 
having Serum Cholesterol level more than 200 mg/dl.  Therefore the high 
Serum cholesterol levels are having influence over the occurrence of AMI.  
Increased Serum Cholesterol   α  occurrence of AMI 
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TABLE NO. 23. 
FREQUENCY TABLE FOR SERUM HDL  
 
HDL Frequency Percent 
Valid 
Less than 40 30 75% 
More than 40 10 25% 
 Total 40 100.0 
 
 
 From the table it is evident that around 75% of patients with AMI are 
having Serum HDL levels less than 40 mg/dl and remaining 25% of patients 
with AMI are having HDL levels more than 40mg/dl.    
 Serum HDL 1/α occurrence of AMI.  
 Therefore from the table it is evident that low level of HDL is having 
influence over the occurrence of AMI.  The high levels of Serum HDL will 
prevent the occurrence of AMI.   
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 The present study was undertaken in patients who were admitted with 
clinical features of AMI in ICCU Thanjavur Medical College, Thanjavur. The 
study was started during November 2009 and was concluded during June 
2010.  The patients were in the age group of between 45 – 65 years including 
both genders with or without associated risk factors like Hypertension, 
Diabetes Mellitus, Hypercholesterolemia, etc. The levels of Serum Neopterin 
were estimated both in the study group and the control group and the levels 
were statistically correlated with other biochemical factors and clinical 
features.  
 
 Serum Neopterin levels were more than normal in the entire study 
group which signifies that Serum Neopterin levels were increased in AMI. The 
statistical correlation between the high levels of Neopterin and AMI was found 
to be highly significant [P(0.000) at 0.01 level 2 tailed].  In contrast Serum 
Neopterin level were found to be within normal limits in the control group 
which signifies that there is no disease activity in this group.  
 
 The high Serum Neopterin levels were associated with Massive 
Adverse Cardiac Events (MACE) like Cardiac Arrythmias, Cardiac Blocks, 
Cardiogenic Shock, Cardiac Failure, etc.  
 
 The correlation between the higher levels of Serum Neopterin more 
than 25 nmol/lit and the occurrence of MACE in the patients was statistically 
significant [P (0.000) at 0.01 level 2 tailed].   
 
 Hence, Neopterin can be considered not only as a biomarker for 
disease activity but also a prognostic marker to identify the high risk patients 
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during treatment and to implement emergency and essential medical 
intervention to prevent mortality.  The study group with high Serum Neopterin 
levels were followed up critically during their hospitalisation and it is evident 
from the study that the occurrence of MACE and mortality is highly significant 
[P(0.000) at 0.01 level 2 tailed].  According to the above study it is proved that 
Serum levels of Neopterin can be considered as an independent  biomarker  
for the disease activity and for the prognostic activity in AMI. 
 
 There is correlation between Serum Neopterin more than 25 nmol/lit 
and with previous history of hospitalisation and there is statistically significant 
correlation [P(0.000) at 0.01 level 2 tailed].  
 
 There is significant correlation with high levels of Serum Neopterin 
more than 25 and the occurrence of Death in patients with AMI.   The 
statistical analysis shows that highly significant correlation [P(0.000) at 0.01 
level 2 tailed] is found.       
 
 Apart from the above the Serum Neopterin levels were correlated with 
other biochemical markers like fasting blood glucose, lipid profile, CKMB 
levels and hypertension. 
 
 A significant correlation was found between the levels of Serum 
Neopterin and CKMB levels in the study group. And this correlation was found 
to be statistically significant [P(0.000) at 0.01 level 2 tailed]. 
 
 Serum Neopterin levels were compared with fasting blood glucose, 
lipid profile and the correlation was found to be not significant statistically. The 
Serum Neopterin levels were correlated in the study group who had 
hypertension and there is significant correlation. 
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 From these studies the major finding is that Neopterin, a biomarker for 
monocyte / macrophage activation and it is a prognostic marker to predict 
adverse cardiac events in patients suffering from AMI.  When the levels of 
CKMB were added the disease activity was proved even stronger due to the 
statistically significant correlation that exists between higher Serum Neopterin 
levels and higher CKMB levels.  
 
 The studies reviewed, have demonstrated that Neopterin level is an 
important predictor of future cardiac as well as vascular adverse event.  In 
particular, Neopterin levels predict future major cardiac and vascular adverse 
events in patients presenting with chronic coronary artery disease with acute 
coronary syndromes.  In those with many of the above cited studies underline 
the strong association between high Neopterin levels and complex 
atherosclerotic lesions but not with disease extension giving account for the 
prognostic properties of Neopterin.  This renders this molecule a useful 
marker of atherosclerotic plaque activity, permitting the identification of the 
subjects at highest risk for MACE. 
 
 Taken together, observations from all the studies reviewed propose the 
existence of a strong link between high Neopterin levels and cardiovascular 
risk profile, suggesting a potential clinical use of Neopterin as a marker for 
disease activity in subjects with cardiovascular disease.  This could help in 
identifying patients who are at a higher risk of developing cardiovascular 
adverse events who might benefit from urgent preventive strategies 
exploitation or extensive diagnostic work-up, as well as actual therapy, 
depending from their co-morbidities. 
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SUMMARY  
 
 The major finding of this study is that Neopterin a marker for monocyte/ 
macrophage activation is predictive for adverse cardiac events in patients with 
AMI. This study has led to the understanding that inflammation, has reflected 
by the levels of Serum Neopterin, which is a major determinant of short term 
outcome in the study group. The results of this study show that Neopterin, a 
marker of macrophage activation, predicts adverse cardiovascular events 
during follow-up in patients with AMI.  
 
 By estimating the serum levels of Neopterin, detection of disease 
activity and intervention of MACE in AMI patients are possible and the 
mortality can be reduced in patients with AMI. 
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CONCLUSION  
 
 In this study it is proved that monocyte / macrophage activation in AMI 
is reflected by the levels of Neopterin and a strong correlation was found 
between high levels of Neopterin and MACE.  
 
 To conclude Neopterin concentrations are usually increased in AMI. 
Highly elevated Neopterin concentrations are among the best predictors of 
adverse outcome in patients with AMI risk. 
 
 Braunwald had initially proposed risk stratification based on the History, 
Physical examination and Electrocardiogram. 
 
 The American college of Cardiology / American Heart Association   
guide lines Committee later refined and incorporated cardiac markers for risk 
stratification.  
 
 This study postulates that Neopterin can be considered as a new novel 
Biomarker for the disease activity in AMI and also as a prognostic marker for 
risk stratification in AMI to prevent mortality and MACE. 
 
 
 
 
 
 
 
NEOPTERIN  
 
 
 
 
 
 
 
IUPAC Name  2-amino-6-(1, 2, 3-trihydroxypropyl)-1H-pteridin-4-one 
 
Molecular formula  C9H11N5O4  
 
Molar mass   253.215 g/mol 
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Pathogenesis of ACS  
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FIG. IV 
Circulating levels of inflammatory markers provide a reflection of the 
underlying inflammatory response  
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MASTER CHART  
TESTS  
Sl. No. Age Sex BP FBG CK-MB N PH MACE D Sr.Choles TGL HDL LDL VLDL 
1 52 I 120/80 120 42 99.6 IV IV IV 238 139 30 180 28 
2 55 I 110/76 140 51 11.4 III III III 258 114 39 196 23 
3 62 II 100/78 146 26 10.6 III III III 216 124 47 144 25 
4 48 I 140/96 92 22 71.7 IV IV IV 192 106 34 137 21 
5 45 I 130/92 86 56 6.9 III III III 213 132 46 141 26 
6 56 II 160/94 106 82 26.9 IV IV III 144 137 26 91 27 
7 58 I 170/98 100 26 29.5 III IV III 200 117 36 141 23 
8 60 I 120/76 76 24 20.1 III III III 227 114 41 163 24 
9 44 I 110/86 160 36 30.3 IV IV IV 189 119 22 143 24 
10 59 II 100/70 76 30 12.2 III III III 222 126 33 164 25 
11 50 I 160/100 110 62 26.9 IV IV IV 151 103 36 94 21 
12 54 I 120/82 96 74 29.5 IV IV III 192 115 36 133 21 
13 55 I 110/76 90 86 9.36 III III III 185 122 36 125 24 
14 64 II 148/100 110 61 20.1 III III III 189 180 22 131 36 
15 60 II 136/92 130 58 20.6 III III III 259 114 39 196 23 
16 55 I 120/80 170 67 30 IV IV IV 202 104 52 129 21 
17 60 II 110/72 86 88 18.3 III III III 216 124 47 144 25 
18 42 I 170/94 112 44 30.5 IV IV IV 178 124 40 113 25 
19 58 I 160/100 136 36 34.4 III IV IV 172 113 41 108 23 
20 59 I 110/82 76 29 34.9 IV IV III 260 133 41 192 27 
21 60 I 110/76 100 37 26.4 III IV III 166 134 22 117 27 
22 65 II 120/80 90 40 13.2 III III III 276 176 20 221 35 
23 50 I 142/98 160 27 80.9 IV IV IV 189 119 33 132 24 
24 54 I 160/100 90 20 36.2 IV IV IV 194 134 37 130 27 
25 56 I 110/82 84 46 17.1 III III III 227 136 22 178 27 
26 51 II 110/72 90 62 28.9 III IV III 236 136 33 176 27 
27 52 I 142/86 100 24 19.5 III III III 241 125 22 194 25 
28 64 I 160/90 110 20 31.2 III IV IV 203 120 40 139 24 
29 62 I 160/100 90 22 74.4 IV IV IV 201 165 33 135 33 
30 56 I 120/80 130 34 21.5 III IV III 264 143 43 192 29 
31 54 I 120/80 120 38 28.1 IV IV III 241 133 31 183 27 
32 58 I 124/82 122 20 15.3 III III III 144 137 26 91 27 
33 62 II 110/72 100 76 14.7 III III III 299 144 51 219 29 
34 61 I 150/96 116 21 19.63 III III III 213 132 46 141 26 
35 54 II 140/90 96 38 16.1 III III III 251 123 27 199 25 
36 59 I 120/82 110 44 19.36 III III III 179 160 31 116 32 
37 65 I 120/80 122 18 32.5 IV IV III 226 127 38 163 25 
38 60 II 110/72 122 26 32.6 III IV IV 189 119 22 143 24 
39 59 II 100/76 116 46 44.6 IV IV IV 177 134 30 120 27 
40 62 I 120/80 100 82 26.2 III IV III 258 133 39 192 27 
CONTROLS 
41. 65 I 120/80 115 20 5.5 III III III 127 150 25 72 30 
42. 55 I 120/80 120 16 6.2 III III III 158 133 39 92 27 
43. 61 I 130/94 110 26 8.6 III III III 179 160 31 116 32 
44. 58 II 120/80 92 25 7.6 III III III 176 170 40 102 34 
45. 42 I 160/100 106 20 9.63 III III III 141 115 43 75 23 
46. 64 I 120/80 86 88 5.6 III III III 171 122 40 107 24 
47. 60 I 120/82 100 42 6.2 III III III 173 145 45 99 29 
48. 59 I 160/100 96 40 9.2 III III III 156 130 32 98 26 
49. 60 II 120/80 100 24 9.72 III III III 186 126 49 112 25 
50. 52 I 120/80 102 25 7.8 III III III 171 122 40 107 24 
51. 53 I 120/82 100 22 5.05 III III III 172 113 41 108 23 
52. 56 I 120/80 90 20 7.09 III III III 145 120 43 78 24 
53. 46 I 140/90 160 18 6.03 III III III 195 135 50 118 27 
54. 50 I 112/82 100 15 7.8 III III III 165 145 49 87 29 
55. 51 II 118/82 140 24 5.25 III III III 183 138 51 114 28 
56. 48 II 150/96 126 19 6.05 III III III 148 152 48 69 31 
57. 64 I 140/86 86 12 5.05 III III III 159 130 52 81 26 
58. 63 II 122/82 72 23 9.82 III III III 179 142 50 119 28 
59. 65 I 144/100 112 17 6.06 III III III 188 98 45 115 18 
60. 55 I 120/80 96 26 4.62 III III III 193 100 43 130 20 
61. 65 I 120/84 126 16 6.26 III III III 156 160 42 82 32 
62. 62 II 126/82 82 11 5.92 III III III 150 86 45 46 18 
63. 45 I 120/80 100 20 6.5 III III III 148 126 51 50 25 
64. 51 I 140/96 100 22 7.01 III III III 145 72 59 72 14 
65. 56 II 130/80 136 19 8.92 III III III 161 155 46 84 31 
66. 60 II 122/82 172 24 6.62 III III III 186 138 52 106 28 
67. 55 I 146/80 166 25 5.72 III III III 172 126 49 98 25 
68. 48 I 120/80 76 11 6.06 III III III 160 140 66 66 28 
69. 52 I 160/90 100 10 8.04 III III III 138 140 52 58 28 
70. 45 I 120/82 96 12 6.06 III III III 152 126 60 67 25 
71. 60 II 120/82 144 22 6.06 III III III 145 72 59 72 14 
72. 62 II 110/80 100 20 7.02 III III III 150 86 35 97 18 
73. 55 I 120/84 100 21 8.22 III III III 148 126 51 72 25 
74. 50 I 120/80 112 15 6.45 III III III 167 141 47 92 28 
75. 49 I 110/72 100 19 5.23 III III III 171 165 45 93 33 
76. 55 I 120/84 100 21 8.22 III III III 148 126 51 72 25 
77. 50 I 120/80 112 15 6.45 III III III 167 141 47 92 28 
78. 49 I 110/72 100 19 5.23 III III III 171 165 45 93 33 
79. 60 II 120/72 82 24 5.63 III III III 154 155 49 74 31 
80. 52 I 110/80 76 20 4.66 III III III 200 128 58 120 22 
 
  I  : Male ;  II : Female ;   III  : Negative;  IV : Positive  For BP – A & B 
A = Systolic BP1 
B = Diastolic BP2  
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